Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1436-3305
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer ; day:22 ; month:11 ; year:2018 ; pages:1
Gastric cancer ; (22.11.2018), 1
- Creator
-
Yagi, Shusuke
Wakatsuki, Takeru
Yamamoto, Noriko
Chin, Keisho
Takahari, Daisuke
Ogura, Mariko
Ichimura, Takashi
Nakayama, Izuma
Osumi, Hiroki
Shinozaki, Eiji
Suenaga, Mitsukuni
Fujisaki, Junko
Ishikawa, Yuichi
Yamaguchi, Kensei
Namikawa, Ken
Horiuchi, Yusuke
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10120-018-0900-4
- URN
-
urn:nbn:de:101:1-2019010822152719379521
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yagi, Shusuke
- Wakatsuki, Takeru
- Yamamoto, Noriko
- Chin, Keisho
- Takahari, Daisuke
- Ogura, Mariko
- Ichimura, Takashi
- Nakayama, Izuma
- Osumi, Hiroki
- Shinozaki, Eiji
- Suenaga, Mitsukuni
- Fujisaki, Junko
- Ishikawa, Yuichi
- Yamaguchi, Kensei
- Namikawa, Ken
- Horiuchi, Yusuke
- SpringerLink (Online service)
Other Objects (12)
Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Enhertu (Trastuzumab-Deruxtecan) : Therapieerfahrungen bei Patient*innen mit HER2-positivem und HER2-low fortgeschrittenem Mammakarzinom
Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Enhertu (Trastuzumab-Deruxtecan) : Therapieerfahrungen bei Patient*innen mit HER2-positivem und HER2-low fortgeschrittenem Mammakarzinom
Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers